Highest-materiality recent filing
Vaccinex voluntarily delists from Nasdaq; Form 25 filing expected March 17, 2025
Nasdaq trading suspended since December 18, 2024 following a hearing panel determination to delist.
Vaccinex receives Nasdaq delisting notice; trading suspended Dec 18, 2024
Nasdaq Hearings Panel determined to delist VCNX for failing to maintain $2.5M minimum stockholders' equity.
Vaccinex raises $2.15M in private placement of stock and pre-funded warrants
Issued 76,909 shares at $3.25/share and pre-funded warrants for 584,646 shares at $3.2499 each.
Vaccinex receives Nasdaq delisting notice for failing equity standard; will appeal
Company failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement for continued listing.
Vaccinex raises ~$6.2M via warrant exercise & new warrant issuance; insiders participate
Holders exercised 1,067,492 existing warrants at $5.636/share; gross proceeds ~$6.2M.
Vaccinex calls warrants after positive Alzheimer's trial FDG-PET signal
Warrants from Oct/Nov 2023, Feb/Mar 2024 financings called for cancellation at $0.0001/share.
Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership
Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.
Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's
Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.
Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study
Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.
Vaccinex receives Nasdaq notice for failing minimum equity requirement
Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.
Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants
Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).
Vaccinex closes $1.5M registered direct offering of 193K shares and warrants at $7.77 combined
Closed registered direct offering of 193,000 shares and warrants for 193,000 shares at $7.77 per unit.
Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance
Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.
Vaccinex raises ~$3.7M in private placement of common stock and warrants
Issues 3.84M shares and warrants for 3.84M shares at $0.725 per unit; also 1.27M pre-funded warrants at $0.7249.
Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.
Vaccinex faces Nasdaq delisting over bid price; appeals, reports equity compliance
Received Nasdaq delisting determination on Oct 10, 2023 for failing minimum bid price compliance (bid below $1 for 30 days).
Vaccinex raises ~$8.7M in public offering of common stock and warrants
Sold 9.6M share equivalents (7.6M shares + 2M pre-funded warrants) at $1.00 per unit, raising ~$8.7M net.
Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.
Vaccinex implements 1-for-15 reverse stock split effective Sept 25, 2023
Reverse stock split at 1-for-15 ratio, effective 5:00 p.m. ET on September 25, 2023.
Vaccinex shareholders approve 1:15 reverse stock split; board sets ratio, effective Sept 2023
Stockholders approved reverse stock split amendment with 43,464,926 votes for, 2,041,760 against, 135,207 abstained.
Vaccinex raises ~$650K in private placement of 3.14M shares at $0.207/share
Issued 3,140,095 shares to accredited investors at $0.207 per share for gross proceeds of approximately $650,000.
Vaccinex receives Nasdaq delisting notice for failing to meet $2.5M equity minimum
Stockholders' equity $2.4M as of March 31, 2023; below Nasdaq's $2.5M minimum.
Vaccinex raises ~$2.96M via private placement of 7.9M shares at $0.37428
Sold 7,908,516 shares at $0.37428/share for $2.96M gross proceeds; closed May 15, 2023.
Vaccinex raises ~$2.04M in private placement at $0.41/share; insider participation
Sold 4,975,608 shares at $0.41/share for gross proceeds of ~$2.04 million to three investors, including affiliates of CEO and chairman.
Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023
Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.
Vaccinex raises $3.8M via private placement of 7.14M shares at $0.5293 per share
Issued 7,142,496 shares to accredited investors for gross proceeds of ~$3.8 million.
Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination
Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.
Vaccinex receives Nasdaq delisting notice for bid price below $1.00
Nasdaq letter on Oct 10, 2022: common stock bid price below $1.00 for 30 consecutive days through Oct 7.
Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.
Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.
Vaccinex raises $9.7M in private placement of 8.75M shares at $1.11; January equity total $13.2M
Private placement closed Jan 31 with 8,747,744 shares at $1.11/share; gross proceeds ~$9.7M after amendment adding 2.8M shares.
Vaccinex reports 2 complete responses in first 3 patients in Phase 1b KEYNOTE-B84 study for HNSCC
Two of three patients in Phase 1b safety segment achieved complete responses per RECIST v1.1.
On March 18, 2025, Bala S. Manian informed Vaccinex, Inc. (the “Company”) of his resignation as a director of the Company effective immediately.
On September 10, 2024, Chrystyna Bedrij Stecyk informed Vaccinex, Inc. (the “Company”) of her resignation as a director of the Company effective immediately.
On February 27, 2024, Scott E. Royer notified Vaccinex Inc. (the “Company”) of his decision to retire from his position as the Company’s Chief Financial Officer effective March 14, 2024.
effective upon Mr. Royer’s retirement on March 14, 2024, Jill Sanchez, age 52, will serve as the Company’s Interim Chief Financial Officer and as its Principal Financial Officer and Principal Accounting Officer.
On March 3, 2022, Jeff Goater informed Vaccinex, Inc. (the “Company”) that due to new responsibilities and conflicting demands on his time, he will not stand for re-election as a director at the Company’s 2022 annual meeting of stockholders.
Max materiality 0.90 · Median 0.60 · Most common event other_material